Figure 1 | Scientific Reports

Figure 1

From: Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment

Figure 1

Changes in the mean best-corrected visual acuity (BCVA) expressed as the logarithm of the minimal angle of resolution during the 24-month follow-up, where anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration (AMD) was employed. At 24 months, the BCVA of eyes with only subretinal fluid (SRF) during the maintenance phase was comparable to that of eyes without exudative recurrence (P = 0.621) and significantly better than that of eyes with exudation except for cases of SRF alone during the maintenance phase (Bonferroni correction after one-way analysis of variance, P < 0.001).

Back to article page